The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
Official Title: A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Study ID: NCT02985957
Brief Summary: The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Local Institution - 0074, Tucson, Arizona, United States
Local Institution - 0046, Marietta, Georgia, United States
Local Institution - 0011, Chicago, Illinois, United States
Local Institution - 0076, Minneapolis, Minnesota, United States
Local Institution - 0008, Saint Louis, Missouri, United States
Local Institution - 0075, Las Vegas, Nevada, United States
Local Institution - 0078, Albany, New York, United States
Local Institution - 0065, Lake Success, New York, United States
Local Institution - 0001, New York, New York, United States
Local Institution - 0077, Tigard, Oregon, United States
Local Institution - 0047, Allentown, Pennsylvania, United States
Local Institution - 0010, Philadelphia, Pennsylvania, United States
Local Institution - 0067, Charleston, South Carolina, United States
Local Institution - 0079, Austin, Texas, United States
Local Institution - 0002, Houston, Texas, United States
Local Institution - 0027, Gosford, New South Wales, Australia
Local Institution - 0059, Wahroonga, New South Wales, Australia
Local Institution - 0029, Westmead, New South Wales, Australia
Local Institution - 0028, Southport, Queensland, Australia
Local Institution - 0043, Woolloongabba, Queensland, Australia
Local Institution - 0030, Elizabeth Vale, South Australia, Australia
Local Institution - 0031, Clayton, Victoria, Australia
Local Institution - 0048, Wien, , Austria
Local Institution - 0044, Montreal, Quebec, Canada
Local Institution - 0063, Aarhus N, Midtjylland, Denmark
Local Institution - 0062, Aalborg, , Denmark
Local Institution - 0061, Kobenhavn O, , Denmark
Local Institution - 0060, Odense, , Denmark
Local Institution - 0009, Clermont-ferrand, , France
Local Institution - 0005, Lyon, , France
Local Institution - 0004, Marseille Cedex 9, , France
Local Institution - 0003, Villejuif, , France
Local Institution - 0038, Göttingen, Niedersachsen, Germany
Local Institution - 0041, Braunschweig, , Germany
Local Institution - 0032, Dresden, , Germany
Local Institution - 0019, Herne, , Germany
Local Institution - 0017, Jena, , Germany
Local Institution - 0018, Muenster, , Germany
Local Institution - 0034, Munich, , Germany
Local Institution - 0037, Nuernberg, , Germany
Local Institution - 0042, Nuertingen, , Germany
Local Institution - 0036, Rostock, , Germany
Local Institution - 0033, Tuebingen, , Germany
Local Institution - 0035, Wesel, , Germany
Local Institution - 0071, Arezzo, , Italy
Local Institution - 0052, Milano, , Italy
Local Institution - 0053, Napoli, , Italy
Local Institution - 0072, Parma, , Italy
Local Institution - 0051, Terni, , Italy
Local Institution - 0055, Kraków, Małopolskie, Poland
Local Institution - 0066, Koszalin, , Poland
Local Institution - 0054, Warszawa, , Poland
Local Institution - 0022, Madrid, Sede Madrid, Spain
Local Institution - 0026, Badajoz, , Spain
Local Institution - 0025, Barcelona, , Spain
Local Institution - 0020, Madrid, , Spain
Local Institution - 0021, Madrid, , Spain
Local Institution - 0024, Malaga, , Spain
Local Institution - 0023, Santiago Compostela, , Spain
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR